secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-032096
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 Therapeutics reports Q1 net loss $18.3M; files first CMP-002 regulatory submission in Australia
--------------------------------------------------------------------------------

- Cash and equivalents $99.2M as of 3/31/26, down from $109.5M; runway expected into 2028.
- Net loss $18.3M vs $12.4M YoY, including $6.2M non-cash loss on derivative tranche liability.
- Submitted first regulatory filing for CMP-002 (SYNGAP1) in Australia; global Phase 1/2 trial anticipated in 2H 2026.
- EMA granted orphan designation for CMP-002; FDA ODD application pending.
- Appointed Michael MacLean to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/0001628280-26-032096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/camp-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer